Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 8,665 |
|
|||||
| News | - | ||||||
| Day High | 2.01 | Low High |
|||||
| Day Low | 1.91 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Can Fite BioPharma Ltd | CANF | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.06 | 3.13% | 1.98 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.94 | 1.91 | 2.01 | 1.98 | 1.92 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 71 | 8,665 | $ 1.97 | $ 17,050 | - | 1.7051 - 3.33 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 20:00:00 | 100 | $ 1.98 | USD |
Can Fite BioPharma Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 1.50B | - | 743k | -7.63M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Can Fite BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CANF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.98 | 2.07 | 1.91 | 1.95 | 7,592 | 0.00 | 0.00% |
| 1 Month | 2.23 | 2.71 | 1.91 | 2.20 | 18,778 | -0.25 | -11.21% |
| 3 Months | 2.07 | 2.71 | 1.91 | 2.15 | 17,538 | -0.09 | -4.35% |
| 6 Months | 1.85 | 2.80 | 1.81 | 2.14 | 59,077 | 0.13 | 7.03% |
| 1 Year | 1.76 | 3.33 | 1.7051 | 2.23 | 40,661 | 0.22 | 12.50% |
| 3 Years | 22.20 | 26.20 | 1.52 | 17.19 | 462,646 | -20.22 | -91.08% |
| 5 Years | 5.40 | 88.765 | 1.52 | 21.48 | 720,029 | -3.42 | -63.33% |
Can Fite BioPharma Description
| Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH). |
